Publications

1. Muniz M, Sartor O, Orme JJ, Koch RM, Rosenow HR, Mahmoud AM, Andrews JR, Kase AM, Riaz IB, Belge Bilgin G, Thorpe MP, Kendi AT, Johnson GB, Ravi P, Kwon ED, Childs DS. Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [(177)Lu]Lu-PSMA-617. J Nucl Med. 2024 Oct 30 [Epub ahead of print]
   View PubMed
2. Choudry MM, Durant AM, Edmonds VS, Warren CJ, Kunze KL, Golafshar MA, Nielsen SM, Esplin ED, Andrews JR, Samadder NJ, Tyson MD. Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study. J Urol. 2024 Oct; 212 (4):590-599 Epub 2024 June 11
   View PubMed
3. Ahmed ME, Mahmoud AM, Reitano G, Zeina W, Lehner K, Day CA, Riaz I, Childs DS, Orme JJ, Tuba Kendi A, Johnson GB, Jeffrey Karnes R, Kwon ED, Andrews JR. Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same? Eur Urol Open Sci. 2024 Aug; 66:38-45 Epub 2024 June 26
   View PubMed
4. Ahmed ME, Lee MS, Mahmoud AM, Joshi VB, Gopalakrishna A, Bole R, Haloi R, Kendi AT, Bold MS, Bryce AH, Karnes RJ, Kwon ED, Childs DS, Andrews JR. Early PSA decline after starting second-generation hormone therapy in the post-docetaxel setting predicts cancer-specific survival in metastatic castrate-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024 Jun; 27 (2):334-338 Epub 2023 Nov 07
   View PubMed
5. Muniz M, Loprinzi CL, Orme JJ, Koch RM, Mahmoud AM, Kase AM, Riaz IB, Andrews JR, Thorpe MP, Johnson GB, Kendi AT, Kwon ED, Nauseef JT, Morgans AK, Sartor O, Childs DS. Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going. Cancer Treat Rev. 2024 Jun; 127:102748 Epub 2024 Apr 30
   View PubMed
6. Mahmoud AM, Moustafa A, Day C, Ahmed ME, Zeina W, Marzouk UM, Basourakos S, Haloi R, Mahon M, Muniz M, Childs DS, Orme JJ, Riaz IB, Kendi AT, Stish BJ, Davis BJ, Kwon ED, Andrews JR. Prostate Cancer Lung Metastasis: Clinical Insights and Therapeutic Strategies. Cancers (Basel). 2024 May 30; 16 (11)
   View PubMed
7. Saxena A, Andrews J, Bryce AH, Riaz IB. Optimal systemic therapy in men with low-volume prostate cancer. Curr Opin Urol. 2024 May 1; 34 (3):183-197 Epub 2024 Mar 05
   View PubMed
8. Mahmoud AM, Orme JJ, Childs DS, Ahmed ME, Rajkumar A, Kwon ED, Andrews JR. Prostate Cancer and Malignant Ascites: The Mayo Clinic Experience With a Rare and Aggressive Disease Progression. Clin Genitourin Cancer. 2024 Apr; 22 (2):291-294 Epub 2023 Nov 23
   View PubMed
9. Mahmoud AM, Ahmed ME, Kendi AT, Thorpe M, Johnson GB, Riaz IB, Orme JJ, Kwon ED, Andrews JR, Childs DS. Low PSA radiographic disease progression on C11-choline PET. BJUI Compass. 2024 Mar; 5 (2):319-324 Epub 2023 Oct 25
   View PubMed
10. Mahmoud AM, Childs DS, Ahmed ME, Tuba Kendi A, Johnson GB, Orme JJ, Stish BJ, Phillips RM, Park SS, Davis BJ, Andrews JR, Kwon ED. Treatment modalities and survival outcomes in prostate cancer parenchymal brain metastasis. Prostate. 2024 Feb; 84 (3):237-244 Epub 2023 Oct 29
    View PubMed
11. Andrews J, An C, Chapin B. Definitions and Management of Oligometastatic Prostate Cancer. American Urological Association (Accepted). 2023.
    
12. Andrews JR, Sood A, Chapin BF. Point-Counterpoint: Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography for Detecting Clinically Node Positive Prostate Cancer. J Urol 2023 Aug; 210 (2):242-243 Epub 2023 May 17
    View PubMed
13. Sood A, Grauer R, Diaz-Insua M, Tewari AK, Hemal AK, Shrivastava A, Peabody JO, Jeong W, Abdollah F, Rudzinski JK, Andrews JR, Gorin MA, Bhandari M, Menon M. 15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer. Prostate Cancer Prostatic Dis. 2023 May 4 Epub 2023 May 04
    View PubMed
14. Britton CJ, Andrews JR, Wallis CJD, Sharma V, Leibovich BC, Thompson RH, Boorjian SA, Bhindi B, Costello BA. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis. Urol Oncol. 2023 Mar; 41 (3):125-136 Epub 2022 Oct 28
    View PubMed
15. Alamiri J, Britton CJ, Ahmed ME, Andrews JR, Higa JL, Dundar A, Karnes RJ, Kwon E, Lowe VJ, Kendi AT, Bold MS, Pagliaro LC. Radiographic paradoxical response in metastatic castrate-resistant prostate cancer (mCRPC) managed with new generation anti-androgens: a retrospective analysis. Prostate. 2022 Dec; 82(16):1483-1490. Epub 2022 Sep 11.
    View PubMed
16. Andrews JR, Ahmed ME, Sharma V, Britton C, Stish B, Phillips R, Kendi AT, Joshi VB, Sood A, Tollefson MK, Boorjian SA, Karnes RJ, Kwon ED. Metastasis-directed Therapy Without Androgen Deprivation Therapy in Solitary Oligorecurrent Prostate Cancer. J Urol. 2022 Dec; 208(6):1240-1249. Epub 2022 Nov 09.
    View PubMed
17. Britton CJ, Andrews JR, Wallis , C, Sharma V, Leibovich BC, Thompson R, Boorjian SA, Bhindi , B, Costello BA. Deferred cytoreductive nephrectomy in the management of metastatic renal cell carcinoma: A systematic review and meta-analysis Urologic Oncology. 2022; 41(3):125-36.
    
18. Sood A, Zhang LT, Keeley J, Butaney M, Stricker M, Andrews JR, Grauer R, Peabody JO, Rogers CG, Menon M, Abdollah F. Optimizing anti-androgen treatment use among men with pathologic lymph-node positive prostate cancer treated with radical prostatectomy: the importance of postoperative PSA kinetics. Prostate Cancer Prostatic Dis. 2022 Jul 6 Epub 2022 July 06
    View PubMed
19. Andrews JR, Lohse CM, Boorjian SA, Leibovich BC, Thompson H, Costello BA, Bhindi B. Outcomes following cytoreductive nephrectomy without immediate postoperative systemic therapy for patients with synchronous metastatic renal cell carcinoma. Urol Oncol. 2022 Apr; 40 (4):166.e1-166.e8 Epub 2022 Feb 13
    View PubMed
20. Jimbo M, Andrews JR, Ahmed ME, Dundar A, Karnes RJ, Bryce AH, Kendi AT, Kwon ED, Lowe VJ, Bold MS. Prognostic role of 11C-choline PET/CT scan in patients with metastatic castrate resistant prostate cancer undergoing primary docetaxel chemotherapy. Prostate. 2022 Jan; 82(1):41-48. Epub 2021 Oct 11.
    View PubMed
21. Hebert KJ, Findlay BL, Yang DY, Houlihan MD, Bole R, Avant RA, Andrews JR, Jimbo M, Ziegelmann MJ, Helo S, Kohler TS. Incidence of Venous Thromboembolism and Safety of Perioperative Subcutaneous Heparin During Inflatable Penile Prosthesis Surgery. Urology. 2021 Nov; 157:155-160 Epub 2021 Aug 16
    View PubMed
22. Herbert KJ, Boswell TC, Bearrick E, Andrews J, Joseph JP, Viers BR. Robotic Puboprostatic Fistula Repair with Holmium Laser Pubic Debridement. Urology. 2021; S0090-4295(21):01000-1.
    
23. Andrews JR, Hebert KJ, Boswell TC, Avant RA, Boonipatt T, Kreutz-Rodrigues L, Bakri K, Houdek MT, Karnes RJ, Viers BR. Pubectomy and urinary reconstruction provides definitive treatment of urosymphyseal fistula following prostate cancer treatment. BJU Int. 2021 Oct; 128(4):460-467. Epub 2021 Feb 17.
    View PubMed
24. Ahmed ME, Andrews JR, Joshi VB, Mynderse LA, Tollefson MK, Karnes RJ, Kwon ED. Patient Satisfaction of Telemedicine Visits in an Advanced Prostate Cancer Clinic During the COVID-19 Pandemic. Mayo Clin Proc Innov Qual Outcomes. 2021 Jun; 5 (3):689-692 Epub 2021 May 26
    View PubMed
25. Westerman ME, Maldonado F, Andrews JR, Sharma V, Trost L, Ziegelmann MJ. Intercourse frequency among men presenting to a sexual health clinic: does age matter? Int J Impot Res. 2021 Jan; 33(1):49-54. Epub 2020 Jan 02.
    View PubMed
26. Ahmed ME, Andrews JR, Alamiri J, Higa J, Haloi R, Alom M, Motterle G, Joshi V, Shah PH, Jeffrey Karnes R, Kwon E. Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes. Prostate. 2020 Oct; 80 (14):1216-1222 Epub 2020 July 31
    View PubMed
27. Andrews JR, Ahmed ME, Motterle G, Albadri ST, Haloi R, Karnes RJ, Kwon ED, Price KA. A Rare Case of Prostate-Specific Antigen-Producing Metastatic Parotid Adenocarcinoma Developing Androgen Receptor Resistance. Mayo Clin Proc Innov Qual Outcomes. 2020 Oct; 4(5):601-607. Epub 2020 Aug 19.
    View PubMed
28. Andrews JR, Sobol I, Frank I, Gettman MT, Thompson RH, Karnes RJ, Boorjian SA, Tollefson MK. Treatment Outcomes in Patients With Symptomatic Lymphoceles Following Radical Prostatectomy Depend Upon Size and Presence of Infection. Urology. 2020 Sep; 143:181-185 Epub 2020 June 17
    View PubMed
29. Manka MG, Yang D, Andrews J, Chalmers B, Hebert K, Kohler TS, Trost L. Intraoperative Use of Betadine Irrigation is Associated With a 9-Fold Increased Likelihood of Penile Prosthesis Infection: Results From a Retrospective Case-Control Study. Sex Med. 2020 Sep; 8 (3):422-427 Epub 2020 June 26
    View PubMed
30. Motterle G, Andrews JR, Morlacco A, Karnes RJ. Predicting Response to Neoadjuvant Chemotherapy in Bladder Cancer. Eur Urol Focus. 2020 Jul 15; 6 (4):642-649 Epub 2019 Nov 08
    View PubMed
31. Motterle G, Ahmed ME, Andrews JR, Moschini M, Kwon ED, Karnes RJ. Tumor Seeding after Robot-Assisted Radical Prostatectomy: Literature Review and Experience from a Single Institution. J Urol. 2020 Jun; 203 (6):1141-1146 Epub 2020 Mar 17
    View PubMed
32. Andrews JR, Ahmed ME, Karnes RJ, Kwon E, Bryce AH. Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter? Prostate. 2020 Apr; 80 (5):399-406 Epub 2020 Jan 13
    View PubMed
33. Ahmed ME, Motterle G, Andrews JR, Moschini M, Kwon ED, Karnes RJ. Salvage Radical Prostatectomy After Robot-assisted Laparoscopic Prostatectomy: Case Series. Clin Genitourin Cancer. 2020 Apr; 18 (2):e202-e207 Epub 2019 Oct 16
    View PubMed
34. Hebert KJ, Joseph J, Boswell T, Andrews J, Husmann DA, Viers BR. Enhanced ambulatory male urethral surgery: a pathway to successful outpatient urethroplasty. Transl Androl Urol. 2020 Feb; 9 (1):23-30
    View PubMed
35. Andrews JR, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, Callstrom MR, Cheville JC, Boorjian SA, Leibovich BC, Thompson RH. Oncologic Outcomes Following Partial Nephrectomy and Percutaneous Ablation for cT1 Renal Masses. Eur Urol. 2019 Aug; 76 (2):244-251 Epub 2019 May 03
    View PubMed
36. Andrews JR, Linder BJ, Scales JA, Elliott DS. Artificial urinary sphincter revision with Quick Connects((R)) versus suture-tie connectors: does technique make a difference? Turk J Urol. 2019 Jul; 45 (4):284-288 Epub 2018 Nov 26
    View PubMed
37. Andrews J, Joseph J, Boonipatt T, Rodrigues L, Bakri K, Houdek M, Viers B. Pubectomy With Urinary Reconstruction Effectively Improves Quality Of Life And Function In Men With Urosymphyseal Fistula After Prostate Cancer Therapy Journal of Urology. 2019; 201(Supplement 4):e885–6.
    
38. Motterle G, Ahmed ME, Andrews JR, Karnes RJ. The Role of Radical Prostatectomy and Lymph Node Dissection in Clinically Node Positive Patients. Front Oncol. 2019; 9:1395 Epub 2019 Dec 10
    View PubMed
39. Viers BR, Linder BJ, Rivera ME, Andrews JR, Rangel LJ, Ziegelmann MJ, Elliott DS. The Impact of Diabetes Mellitus and Obesity on Artificial Urinary Sphincter Outcomes in Men. Urology. 2016 Dec; 98:176-182. Epub 2016 Jun 29.
    View PubMed
40. Martin AD, Nunez RN, Andrews JR, Martin GL, Andrews PE, Castle EP. Outpatient prostatectomy: too much too soon or just what the patient ordered. Urology. 2010 Feb; 75: (2)421-4.
    View PubMed
41. Nunez-Nateras R, Andrews JR, Martin GL, Andrews PE, Humphreys MR, Ferrigni RG, Eversman WG, Castle EP. Accuracy of ultrasound in estimation of prostate weight: comparison of urologists and radiologists. Can J Urol. 2010 Feb; 17: (1)4985-8.
    View PubMed
42. Nunez-Nateras R, Ko EY, Andrews JR, Humphreys MR, Castle EP, Andrews PE. Nephrobronchial fistula secondary to xanthogranulomatous pyelonephritis Current Urology. 2010; 4: (1)45-8.